Table 2.

Chimerism, GVHD, infection, and clinical outcome

Dose level and patient no.	% donor at 6 mo	aGVHD	cGVHD	Viral reactivations	Fungal infection	Autoimmunity	Off study, mo after SCT	Current status*
Dose level 1
P1	100	None	None	CMV/VZV	None	None	—	Alive in CR
P2	100	Grade 4 skin	Ext (skin/liver)	CMV/Adeno	Aspergillus (B/C)	None	8, death from liver failure	Death from liver failure (adeno/GVH)
P3	57 MNCs, 56 grans	None	None	CMV	None	None	8, 2nd SCT for mixed chimerism	Alive in CR after 2nd SCT
P4	97	None	None	None	None	None	6, relapse	Death from disease/infection/hemorrhage
P5	Relapsed	None	None	None	None	None	5, relapse	Death from disease
P6	100	None	None	CMV/VZV/EBV	None	None	9, relapse	Death from disease/infection
P7	74 MNCs, 66 grans	None	None	CMV/EBV	None	None	5, autologous reconstitution/relapse	Death from disease/infection
P8	0 MNCs, 0 grans	None	Not evaluable	CMV	None	None	3, autologous reconstitution	Alive in CR after 2nd SCT
Dose level 2
P9	100	Grade 1 skin	None	EBV	None	None	8, relapse	Alive in relapse
P10	Relapsed	None	None	CMV	None	None	5, death from respiratory failure	Death from interstitial pneumonitis
P11	100	Grade 1 gut	None	EBV	None	None	—	Alive in CR
P12	100	Grade 2 skin	Ext (skin/mouth)	EBV	None	None	—	Alive in CR
P13	100	None	None	CMV/EBV/JC	Pulmonary	AIHA	30, death from multiorgan failure	Death from sepsis + multiorgan failure
P14	100	None	None	None	None	None	7, relapse	Death from disease
P15	100	None	None	CMV/Adeno	Pulmonary	None	7, death from encephalopathy	Death from postinfective encephalopathy
P16	100	None	None	None	None	None	8, relapse	Alive in relapse

MNCs indicates mononuclear cells; grans, granulocytes; B/C, blood cultures; and —, completed study.

^*As of June 2006.